Journal of Current Glaucoma Practice

Register      Login

VOLUME 18 , ISSUE 3 ( July-September, 2024 ) > List of Articles

Original Article

12-month Safety and Efficacy Outcomes of a Standalone Trabecular Bypass Device

Brandon Huynh, Colin Clement, Vuong Nguyen, Stephen O Hagan, Frank Howes, Peter Macken, David Manning, Ridia Lim, Jed Lusthaus, Mitchell Lawlor

Keywords : Glaucoma, iStent inject, Minimally invasive glaucoma surgery, Real world data

Citation Information : Huynh B, Clement C, Nguyen V, O Hagan S, Howes F, Macken P, Manning D, Lim R, Lusthaus J, Lawlor M. 12-month Safety and Efficacy Outcomes of a Standalone Trabecular Bypass Device. J Curr Glaucoma Pract 2024; 18 (3):103-109.

DOI: 10.5005/jp-journals-10078-1447

License: CC BY-NC 4.0

Published Online: 29-10-2024

Copyright Statement:  Copyright © 2024; The Author(s).


Abstract

Purpose: To analyze the outcomes of the iStent inject in a real-world clinical setting as a standalone procedure to lower intraocular pressure (IOP) in open-angle glaucoma. Materials and methods: Patients with open-angle glaucoma having undergone iStent inject insertion without concurrent cataract extraction were included in this multicenter observational real-world study in Australia. Patient data was entered into the Fight Glaucoma Blindness! Registry. Assessments through 12 months included glaucoma subtype, IOP, medications, best-corrected visual acuity (BCVA), secondary surgical procedures, and adverse events. Kaplan–Meier survival curves for outcomes were reported according to the World Glaucoma Association (WGA). Results: Sixty-one eyes from 44 patients with a mean age of 76 ± 11.4 underwent standalone iStent inject implantation. The mean ± SD preoperative IOP was 17.5 ± 7.5 mm Hg, and the mean preoperative number of topical medications was 2.5 ± 1.5. At 12 months postoperatively, there was no statistically significant IOP reduction, while the number of glaucoma medications used was reduced to 1.4 ± 1.5 (p < 0.001). Fourteen point one percent of eyes required a secondary pressure-lowering procedure within the 12-month follow-up window. Conclusion: This assessment of standalone iStent inject implantation did not show any significant reduction in IOP, but there was a significant decrease in medication use in the real-world clinical setting. The procedure is safe with minimal adverse outcomes; however, a subset of patients required secondary procedures within 12 months of follow-up.


PDF Share
  1. Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol 2006;90(3):262–267. DOI: 10.1136/bjo.2005.081224
  2. Tham YC, Li X, Wong TY, et al. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology 2014;121(11):2081–2090. DOI: 10.1016/j.ophtha.2014.05.013
  3. Sihota R, Angmo D, Ramaswamy D, et al. Simplifying “target” intraocular pressure for different stages of primary open-angle glaucoma and primary angle-closure glaucoma. Indian J Ophthalmol 2018;66(4):495–505. DOI: 10.4103/ijo.IJO_1130_17
  4. Heijl A, Leske MC, Bengtsson B, et al. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol 2002;120(10):1268–1279. DOI: 10.1001/archopht.120.10.1268
  5. Gazzard G, Konstantakopoulou E, Garway-Heath D, et al. Selective laser trabeculoplasty versus eye drops for first-line treatment of ocular hypertension and glaucoma (LiGHT): a multicentre randomised controlled trial. Lancet 2019;393(10180):1505–1516. DOI: 10.1016/S0140-6736(18)32213-X
  6. Lusthaus J, Goldberg I. Current management of glaucoma. Med J Aust 2019;210(4):180–187. DOI: 10.5694/mja2.50020
  7. Friedman DS, Okeke CO, Jampel HD, et al. Risk factors for poor adherence to eyedrops in electronically monitored patients with glaucoma. Ophthalmology 2009;116(6):1097–1105. DOI: 10.1016/j.ophtha.2009.01.021
  8. Kosoko O, Quigley HA, Vitale S, et al. Risk factors for noncompliance with glaucoma follow-up visits in a residents’ eye clinic. Ophthalmology 1998;105(11):2105–2111. DOI: 10.1016/S0161-6420(98)91134-4
  9. Gedde SJ, Schiffman JC, Feuer WJ, et al. Treatment outcomes in the Tube Versus Trabeculectomy (TVT) study after five years of follow-up. Am J Ophthalmol 2012;153(5):789–803e2. DOI: 10.1016/j.ajo.2011.10.026
  10. Gedde SJ, Herndon LW, Brandt JD, et al. Postoperative complications in the Tube Versus Trabeculectomy (TVT) study during five years of follow-up. Am J Ophthalmol 2012;153(5):804–814e1. DOI: 10.1016/j.ajo.2011.10.024
  11. Lam K, Lawlor M. Anatomy of the aqueous outflow drainage pathways. In: Minimally Invasive Glaucoma Surgery [Internet]. Springer Singapore; 2021. p. 1. 216 p.
  12. Samuelson TW, Sarkisian SR Jr, Lubeck DM, et al. Prospective, randomized, controlled pivotal trial of an ab interno implanted trabecular micro-bypass in primary open-angle glaucoma and cataract: two-year results. Ophthalmology 2019;126(6):811–821. DOI: 10.1016/j.ophtha.2019.03.006
  13. Samuelson TW, Chang DF, Marquis R, et al. A Schlemm canal microstent for intraocular pressure reduction in primary open-angle glaucoma and cataract: the HORIZON study. Ophthalmology 2019;126(1):29–37. DOI: 10.1016/j.ophtha.2018.05.012
  14. Arriola-Villalobos P, Martinez-de-la-Casa JM, Diaz-Valle D, et al. Glaukos iStent inject® trabecular micro-bypass implantation associated with cataract surgery in patients with coexisting cataract and open-angle glaucoma or ocular hypertension: a long-term study. J Ophthalmol 2016;2016:1056573. DOI: 10.1155/2016/1056573
  15. Clement CI, Howes F, Ioannidis AS, et al. One-year outcomes following implantation of second-generation trabecular micro-bypass stents in conjunction with cataract surgery for various types of glaucoma or ocular hypertension: multicenter, multi-surgeon study. Clin Ophthalmol 2019;13:491–499. DOI: 10.2147/OPTH.S187272
  16. Shalaby WS, Jia J, Katz LJ, et al. iStent inject: comprehensive review. J Cataract Refract Surg 2021;47(3):385–399. DOI: 10.1097/j.jcrs.0000000000000325
  17. Klamann MK, Gonnermann J, Pahlitzsch M, et al. iStent inject in phakic open angle glaucoma. Graefes Arch Clin Exp Ophthalmol 2015;253(6):941–947. DOI: 10.1007/s00417-015-3014-2
  18. Fea AM, Belda JI, Rekas M, et al. Prospective unmasked randomized evaluation of the iStent inject (®) versus two ocular hypotensive agents in patients with primary open-angle glaucoma. Clin Ophthalmol 2014;8:875–882. DOI: 10.2147/OPTH.S59932
  19. Hengerer FH, Auffarth GU, Riffel C, et al. Second-generation trabecular micro-bypass stents as standalone treatment for glaucoma: a 36-month prospective study. Adv Ther 2019;36(7):1606–1617. DOI: 10.1007/s12325-019-00984-9
  20. Voskanyan L, Garcia-Feijoo J, Belda JI, et al. Prospective, unmasked evaluation of the iStent® inject system for open-angle glaucoma: synergy trial. Adv Ther 2014;31(2):189–201. DOI: 10.1007/s12325-014-0095-y
  21. Berdahl J, Voskanyan L, Myers JS, et al. Implantation of two second-generation trabecular micro-bypass stents and topical travoprost in open-angle glaucoma not controlled on two preoperative medications: 18-month follow-up. Clin Exp Ophthalmol 2017;45(8):797–802. DOI: 10.1111/ceo.12958
  22. Lindstrom R, Lewis R, Hornbeak DM, et al. Outcomes following implantation of two second-generation trabecular micro-bypass stents in patients with open-angle glaucoma on one medication: 18-month follow-up. Adv Ther 2016;33(11):2082–2090. DOI: 10.1007/s12325-016-0420-8
  23. Macher T, Haberle H, Wachter J, et al. Trabecular microbypass stents as minimally invasive approach after conventional glaucoma filtration surgery. J Cataract Refract Surg 2018;44(1):50–55. DOI: 10.1016/j.jcrs.2017.10.039
  24. Davids AM, Pahlitzsch M, Boeker A, et al. iStent inject as a reasonable alternative procedure following failed trabeculectomy? Eur J Ophthalmol 2018;28(6):735–740. DOI: 10.1177/1120672117747010
  25. Ahmed IIK, Fea A, Au L, et al. A prospective randomized trial comparing hydrus and iStent microinvasive glaucoma surgery implants for standalone treatment of open-angle glaucoma: the COMPARE study. Ophthalmology 2020;127(1):52–61. DOI: 10.1016/j.ophtha.2019.04.034
  26. Lawlor M, Nguyen V, Brooks A, et al. Efficient capture of high-quality real-world data on treatments for glaucoma: the Fight Glaucoma Blindness! Registry. BMJ Open Ophthalmol 2021;6(1):e000903. DOI: 10.1136/bmjophth-2021-000903
  27. Shaarawy T, Sherwood M, Grehn F. Guidelines on Design and Reporting of Glaucoma Surgical Trials. Kugler Publications; 2009.
  28. Team RC. R: a language and environment for statistical computing. Vienna (Austria): R Foundation for Statistical Computing; 2018.
  29. Therneau TM. A package for survival analysis in R. 2020 [cited 2024 Sep 14]. Available from: https://CRAN.R-project.org/package=survival
  30. Mansberger SL, Gordon MO, Jampel H, et al. Reduction in intraocular pressure after cataract extraction: the ocular hypertension treatment study. Ophthalmology 2012;119(9):1826–1831. DOI: 10.1016/j.ophtha.2012.02.050
  31. Bloom P, Au L. “Minimally invasive glaucoma surgery (MIGS) is a poor substitute for trabeculectomy”-the great debate. Ophthalmol Ther 2018;7(2):203–210. DOI: 10.1007/s40123-018-0135-9
  32. Fan Gaskin JC, Sandhu SS, Walland MJ. Victorian trabeculectomy audit. Clin Exp Ophthalmol 2017;45(7):695–700. DOI: 10.1111/ceo.12948
  33. Kirwan JF, Lockwood AJ, Shah P, et al. Trabeculectomy in the 21st century: a multicenter analysis. Ophthalmology 2013;120(12):2532–2539. DOI: 10.1016/j.ophtha.2013.07.049
  34. Edmunds B, Thompson JR, Salmon JF, et al. The National Survey of Trabeculectomy. II. Variations in operative technique and outcome. Eye (Lond) 2001;15(Pt 4):441–448. DOI: 10.1038/eye.2001.152
  35. Wong MO, Lee JW, Choy BN, et al. Systematic review and meta-analysis on the efficacy of selective laser trabeculoplasty in open-angle glaucoma. Surv Ophthalmol 2015;60(1):36–50. DOI: 10.1016/j.survophthal.2014.06.006
  36. Schlote T, Kynigopoulos M. Selective laser trabeculoplasty (SLT): 1-year results in early and advanced open angle glaucoma. Int Ophthalmol 2016;36(1):55–61. DOI: 10.1007/s10792-015-0079-1
  37. Miraftabi A, Nilforushan N, Nassiri N, et al. Selective laser trabeculoplasty in patients with pseudoexfoliative glaucoma vs primary open angle glaucoma: a one-year comparative study. Int J Ophthalmol 2016;9(3):406–410. DOI: 10.18240/ijo.2016.03.14
  38. Berdahl JP, Khatana AK, Katz LJ, et al. Cost-comparison of two trabecular micro-bypass stents versus selective laser trabeculoplasty or medications only for intraocular pressure control for patients with open-angle glaucoma. J Med Econ 2017;20(7):760–766. DOI: 10.1080/13696998.2017.1327439
  39. Ontario H. iStent for adults with glaucoma: a health technology assessment. Ont Health Technol Assess Ser 2021;21(10):1–42. PMID: 34422143.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.